The Global Health Body Sounds Warning Over Severe Shortage of Weight-Loss Medications
Fewer than a tenth of people who could benefit from GLP-1 drugs including Wegovy are able to get them, warns the WHO as it publishes its initial guidance on the drugs.
Given in excess of 1,000,000,000 people worldwide currently classified as obese, it is advocating for broader and more equitable availability to these injectable treatments.
According to forecasts, more than two billion will be obese by 2030 if no action is taken.
"Our latest guidance affirms that obesity is a long-term condition that can be addressed with thorough and lifelong support," remarked its chief Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and logistical bottlenecks are major hurdles to universal access to the injections that can help people shift considerable body mass, explains the agency.
GLP-1 Therapy Scarcity
Even under the present best projected outlook, the production of GLP-1 therapies might only reach around 100 million people – less than 10% of the global need, as stated by the health organization.
The recommendation encourages countries and companies to increase availability, through approaches including voluntary licensing.
The intellectual property rights on a key compound – the primary component of the drug Wegovy – is scheduled to end in a number of nations in 2026.
The Way Weight-Loss Drugs Function
GLP-1 drugs mimick a body's own hormone to delay gastric emptying, suppress the appetite and enhance the sense of being full so users consume fewer calories.
Individuals commonly begin shedding pounds in the initial weeks of starting on the weekly injections.
Studies indicates patients may regain a significant portion within a year of halting the drug, because their typical appetite come back.
Being above a healthy weight increases your likelihood for developing diseases, such as type 2 diabetes, cardiovascular issues, brain attack, and certain cancers.
Excess weight impacts individuals in all nations and was responsible for over three and a half million fatalities worldwide in 2024, according to the health agency.
